Overview

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborator:
National Psoriasis Foundation
Treatments:
Acitretin
Adalimumab
Etanercept
Methotrexate
Ustekinumab